Full Press Release Details
Kamada to Announce First Quarter 2025 Financial
Results on May 14, 2025
Company to Host Conference Call at 8:30am ET
REHOVOT, Israel, and HOBOKEN, NJ - May
7, 2025 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed
products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release
financial results for the first quarter that ended March 31, 2025, prior to the open of the U.S. financial markets on Wednesday, May 14,
Kamada management will host an investment community
conference call on Wednesday, May 14, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested
parties may participate in the call by dialing 1-877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel), or 1-201-689-8263 (International)
using conference I.D. 1375314. The call will be webcast live on the internet at: https://viavid.webcasts.com/starthere.jsp?ei=1715006&tp_key=c9896a4811.
Kamada Ltd. (the "Company") is a global
biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty
plasma-derived therapies field. The Company's strategy is focused on driving profitable growth through four primary growth pillars:
First, organic growth from its commercial activities, including continued investment in the commercialization and life cycle management
of its proprietary products, which include six FDA-approved specialty plasma-derived products: KEDRAB , CYTOGAM , GLASSIA ,
WINRHO SDF , VARIZIG and HEPAGAM B , as well as KAMRAB , KAMRHO (D) and two types of equine-based anti-snake venom
products, and the products in the distribution segment portfolio, mainly through the launch of several biosimilar products in Israel.
Second: the Company aims to secure significant new business development, in-licensing, collaboration and/or merger and acquisition opportunities,
which are anticipated to enhance the Company's marketed products portfolio and leverage its financial strength and existing commercial
infrastructure to drive long-term growth. Third: the Company is expanding its plasma collection operations to support revenue growth through
the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing demand for hyper-immune plasma.
The Company currently owns three operating plasma collection centers in the United States, in Beaumont Texas, Houston Texas, and San Antonio,
Texas. Lastly, the Company is leveraging its manufacturing, research and development expertise to advance the development and commercialization
of additional product candidates, targeting areas of significant unmet medical need, with the lead product candidate Inhaled AAT, for
which the Company is continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase
3 trial. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company's controlling shareholder, beneficially
owning approximately 38% of the outstanding ordinary shares.